These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
253 related articles for article (PubMed ID: 35727480)
1. ATP, an attractive target for the treatment of refractory chronic cough. Zhang M; Sykes DL; Sadofsky LR; Morice AH Purinergic Signal; 2022 Sep; 18(3):289-305. PubMed ID: 35727480 [TBL] [Abstract][Full Text] [Related]
2. P2X3-Receptor Antagonists as Potential Antitussives: Summary of Current Clinical Trials in Chronic Cough. Dicpinigaitis PV; McGarvey LP; Canning BJ Lung; 2020 Aug; 198(4):609-616. PubMed ID: 32661659 [TBL] [Abstract][Full Text] [Related]
3. Update on the clinical development of gefapixant, a P2X3 receptor antagonist for the treatment of refractory chronic cough. Muccino D; Green S Pulm Pharmacol Ther; 2019 Jun; 56():75-78. PubMed ID: 30880151 [TBL] [Abstract][Full Text] [Related]
4. BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration. Garceau D; Chauret N Pulm Pharmacol Ther; 2019 Jun; 56():56-62. PubMed ID: 30902655 [TBL] [Abstract][Full Text] [Related]
5. Mechanisms and Rationale for Targeted Therapies in Refractory and Unexplained Chronic Cough. Mazzone SB; McGarvey L Clin Pharmacol Ther; 2021 Mar; 109(3):619-636. PubMed ID: 32748976 [TBL] [Abstract][Full Text] [Related]
6. Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial. Smith JA; Kitt MM; Morice AH; Birring SS; McGarvey LP; Sher MR; Li YP; Wu WC; Xu ZJ; Muccino DR; Ford AP; Lancet Respir Med; 2020 Aug; 8(8):775-785. PubMed ID: 32109425 [TBL] [Abstract][Full Text] [Related]
13. Randomised trial of the P2X Niimi A; Saito J; Kamei T; Shinkai M; Ishihara H; Machida M; Miyazaki S Eur Respir J; 2022 Jun; 59(6):. PubMed ID: 34649978 [TBL] [Abstract][Full Text] [Related]
14. Looking ahead to novel therapies for chronic cough. Part 1 - peripheral sensory nerve targeted treatments. Grabczak EM; Dabrowska M; Birring SS; Krenke R Expert Rev Respir Med; 2020 Dec; 14(12):1217-1233. PubMed ID: 32804594 [TBL] [Abstract][Full Text] [Related]
15. The Efficacy and Safety of Gefapixant in a Phase 3b Trial of Patients with Recent-Onset Chronic Cough. McGarvey L; Sher M; Shvarts YG; Lu S; Wu WC; Xu P; Schelfhout J; La Rosa C; Nguyen AM; Reyfman PA; Afzal AS Lung; 2023 Apr; 201(2):111-118. PubMed ID: 36879087 [TBL] [Abstract][Full Text] [Related]
16. Antitussive efficacy of the current treatment protocol for refractory chronic cough: our real-world experience in a retrospective cohort study. Zhang M; Morice AH; Si F; Zhang L; Chen Q; Wang S; Zhu Y; Xu X; Yu L; Qiu Z Ther Adv Respir Dis; 2023; 17():17534666231167716. PubMed ID: 37078383 [TBL] [Abstract][Full Text] [Related]
17. Effects of Renal Impairment on the Pharmacokinetics of Gefapixant, a P2X3 Receptor Antagonist. Nussbaum JC; Hussain A; Min KC; Marbury TC; Lasseter K; Stoch SA; Iwamoto M J Clin Pharmacol; 2022 Nov; 62(11):1435-1444. PubMed ID: 35656754 [TBL] [Abstract][Full Text] [Related]
18. An update and systematic review on drug therapies for the treatment of refractory chronic cough. Ryan NM; Vertigan AE; Birring SS Expert Opin Pharmacother; 2018 May; 19(7):687-711. PubMed ID: 29658795 [TBL] [Abstract][Full Text] [Related]
19. The role of ATP in cough hypersensitivity syndrome: new targets for treatment. Zhang M; Wang S; Yu L; Xu X; Qiu Z J Thorac Dis; 2020 May; 12(5):2781-2790. PubMed ID: 32642186 [TBL] [Abstract][Full Text] [Related]